article
Developing immunotherapies for hard-to-treat cancers
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
List view / Grid view
Immunotherapy
news
Could T-cell immunotherapy be the answer to COVID-19?
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
news
IL-27 could work as potential immunotherapy against cancers
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
news
Researchers develop CAR-T therapy that targets multiple leukaemia sites
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
news
Researchers identify target to improve dendritic cell ability to fight tumours
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
news
Removing macrophages shows success against ovarian cancer in mice
By removing two kinds of macrophages in mice, researchers showed that ovarian tumours in mice were reduced in size and stopped spreading.
news
Collaboration initiated to develop COVID-19 immunotherapy
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
article
TCR therapy – an attractive alternative to CAR T
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
news
Early natural killer cells more effective than adult versions, find researchers
Researchers have shown that natural killer (NK) cells work best as an immunotherapy when in an early stage of development, so could be manufactured from pluripotent stem cells.
whitepaper
Application note: Immuno-oncology
Identifying next generation targets for cancer immunotherapy.
news
Increasing ion channel function in cancer T cells could be new immunotherapy
Researchers have found that there is less calmodulin binding to ion channels in the T cells from cancer patients, presenting a new immunotherapeutic target.
news
CAR T-cell receptors based on scorpion venom show efficacy in mice
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
news
T-cell regulator SLAMF6 may be hindering immunotherapy success
A new study conducted in Israel suggests that T cells’ ability to destroy skin cancer increases in the absence of T-cell regulators called SLAMF6.
news
Mitochondria-boosting compound promotes immunotherapy in mice
Researchers have discovered that a small molecule can help some T cells combat tumours during PD-1 blockade immunotherapy in mice.